Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanuwave Health’s SEC documents can feel like you’re decoding clinical trial data and FDA nuances at the same time. Whether you’re tracing reimbursement risk in a 300-page annual report or scanning for new device revenue in a 10-Q, the stakes are high—especially when chronic wound-care adoption drives valuation. That’s why Stock Titan puts AI-powered summaries on every filing, turning dense medical terminology into plain-English takeaways investors can act on.
Searches like “Sanuwave Health quarterly earnings report 10-Q filing” or “Sanuwave Health 8-K material events explained” land you here because we map each question to the right form. Want insider confidence signals? Our platform streams Sanuwave Health Form 4 insider transactions real-time, flags option exercises, and keeps a historical log under “Sanuwave Health executive stock transactions Form 4.” Need the bigger picture? The Sanuwave Health annual report 10-K simplified section highlights device pipeline progress, R&D spend, and regulatory milestones. For governance detail, the “Sanuwave Health proxy statement executive compensation” tab breaks out PACE-based performance metrics without the legal clutter.
Every filing—from routine “Sanuwave Health insider trading Form 4 transactions” to surprise 8-K updates—is indexed seconds after EDGAR posts. Our AI spots shifts in wound-care reimbursement language, compares quarter-over-quarter revenue, and attaches concise context so you can stop scrolling and start deciding. If you’ve ever typed “understanding Sanuwave Health SEC documents with AI” or looked for “Sanuwave Health earnings report filing analysis,” you’ve just found the place investors rely on for clarity, speed, and total coverage.
Form 4 filing overview – SANUWAVE Health, Inc. (SNWV)
Director Gregory M. Bazar reported one insider transaction dated 30 June 2025. The filing shows an award of 1,574 stock options (right to buy common stock) with an exercise price of $32.86 and an expiration date of 30 June 2030. The options were fully vested at the grant date, and Bazar now beneficially owns 1,574 derivative securities directly. No open-market purchases or sales of common shares were disclosed, and there were no changes to non-derivative share holdings.
The transaction appears to be routine director compensation and represents a limited potential dilution given the company’s outstanding share count. No other financial or operational information was provided in this filing.
FAQ
What is the current stock price of Sanuwave Health (SNWV)?
What is the market cap of Sanuwave Health (SNWV)?
